Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide

Completed · Not applicable · Has a placebo group

Conditions studied: Asthma

In brief

Glucocorticosteroids recently have been shown to have non-genomic actions that are plasma membrane-mediated and do not require gene transcription and translation. One of these non-genomic effects is the inhibition of adrenergic agonist transport into airway vascular smooth muscle cells with an increase of adrenergic agonist concentrations at adrenergic receptor sites and enhance the physiological effects of endogenous adrenergic agonists (e.g. locally released norepinephrine from noradrenergic neurons) or exogenous adrenergic agonists (e.g. inhaled beta-adrenergic agonists).

Key facts

Study ID

NCT01219738

Run by

University of Miami

People needed

20

Starts

2008-07-01

Expected to finish

2012-08-01

Last updated by the study team

2015-01-16

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Twenty lifetime nonsmokers moderate or severe asthmatics; FEV1≥50 of predicted on the screening day

You may not qualify if…

• Women of childbearing potential who do not use accepted birth control measures; pregnant and breast feeding women; Cardiovascular disease and/or use of cardiovascular medication; Subjects with known beta-adrenergic agonist or glucocorticosteroid intolerance; Acute respiratory infection and or acute exacerbation of asthma within four weeks prior to the study; Use of systemic glucocorticosteroids within 4 weeks prior to the study; Daily ICS dose (fluticasone or budesonide) > 500ug; Diabetes mellitus

Where it is running

• Pulmonary Human Research Laboratory, University of Miami, Miller School of Medicine — Miami, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.